In 2024, the FDA approved Rezdiffra, the first medication for NASH.
In March 2024, the Food and Drug Administration granted accelerated approval to Rezdiffra (resmetirom), the first medication for NASH, now known as MASH. Rezdiffra is indicated for adults with NASH who have moderate to advanced liver fibrosis, in conjunction with a healthy diet and exercise. Clinical studies showed that the once-daily pill reduces liver fat accumulation, improves MASH and reduces fibrosis.
